PI3K/AKT signaling pathway and cancer: An updated review

Annals of Medicine

Volumn 46, Issue 6, 2014, Pages 372-383

  Martini, Miriam ^a   De Santis, Maria Chiara ^a   Braccini, Laura ^a   Gulluni, Federico ^a   Hirsch, Emilio ^a  

^a Center for Molecular Biotechnology   (Italy)

Author keywords

Cancer; MTOR; PI3K; PI3K inhibitors; Ras; Signaling

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR; BEVACIZUMAB; CETUXIMAB; DACTOLISIB; DASATINIB; DOCETAXEL; DOXORUBICIN; EVEROLIMUS; GLUCOSE TRANSPORTER 4; INTERSECTIN; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P110; PROTEIN P85; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SELUMETINIB; TEMSIROLIMUS;

ADVANCED CANCER; CANCER THERAPY; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL SURVIVAL; CELLULAR DISTRIBUTION; DNA MODIFICATION; ENZYME ACTIVE SITE; ENZYME PHOSPHORYLATION; EXON; GENE MUTATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROTEIN SYNTHESIS; REVIEW; SECOND MESSENGER; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TISSUE DISTRIBUTION; TREATMENT RESPONSE; ANIMAL; GENETICS; METABOLISM; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; HUMANS; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84907063686     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2014.912836     Document Type: Review

References (147)

1. Kaplan DR, Whitman M, Schaffh ausen B, et al. Common elements in growth factor stimulation and oncogenic transformation: 85 kd phosphoprotein and phosphatidylinositol kinase activity. Cell. 1987 ; 50 : 1021-9
2. Whitman M, Kaplan DR, Schaffh ausen B , e t a l. A ssociation of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature. 1985; 315: 239-42
3. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specifi c PI3K signalling. Nat Rev Mol Cell Biol. 2010 ; 11 : 329-41
4. Geering B, Cutillas PR, Nock G, et al. Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc Natl Acad Sci U S A. 2007 ; 104 : 7809-14
5. Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene. 2008; 27: 5486-96
6. Burgering BM, Coff er P J. P rotein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature. 1995; 376: 599-602
7. Pearce LR, Komander D, Alessi DR. The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol. 2010 ; 11 : 9-22
8. Wick MJ , Dong LQ , Riojas RA , et al. Mechanism of phosphorylation of protein kinase B/Akt by a constitutively active 3-phosphoinositidedependent protein kinase-1. J Biol Chem. 2000 ; 275 : 40400-6
9. Nave BT, Ouwens M, Withers DJ, et al. Mammalian target of rapamycin is a direct target for protein kinase B: identifi cation of a convergence point for opposing eff ects of insulin and amino-Acid defi ciency on protein translation. Biochem J. 1999 ; 344(Pt 2) : 427-31
10. Aoki M, Blazek E, Vogt PK. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci U S A. 2001; 98: 136-41
11. Hawkins PT, Anderson KE, Davidson K, Stephens LR. Signalling through Class I PI3Ks in mammalian cells. Biochem Soc Trans. 2006 ; 34 : 647-62
12. Qiu RG, Chen J, Kirn D, et al. An essential role for Rac in Ras transformation. Nature. 1995; 374: 457-9
13. Welch HC, Coadwell WJ, Ellson C D, e t a l. P -Rex1, a PtdIns(3,4,5)P3-And Gbetaγ-regulated guanine-nucleotide exchange factor for Rac. Cell. 2002 ; 108 : 809-21
14. Han J, Luby-Phelps K, Das B, et al. Role of substrates and products of PI 3-kinase in regulating activation of Rac-related guanosine triphosphatases by Vav. Science. 1998; 279: 558-60
15. Lindvall J, Islam TC. Interaction of Btk and Akt in B cell signaling. Biochem Biophys Res Commun. 2002; 293: 1319-26
16. Rameh LE, Arvidsson A, Carraway KL 3rd, et al. A comparative analysis of the phosphoinositide binding specifi city of pleckstrin homology domains. J Biol Chem. 1997; 272: 22059-66
17. Di Paolo G, De Camilli P. Phosphoinositides in cell regulation and membrane dynamics. Nature. 2006; 443: 651-7
18. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997 ; 275 : 1943-7
19. A li I U, S chriml L M, D ean M. M utational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst. 1999; 91: 1922-32
20. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-Trisphosphate. J Biol Chem. 1998; 273: 13375-8
21. Zhang JG, Wang JJ, Zhao F, et al. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in nonsmall cell lung cancer (NSCLC). Clin Chim Acta. 2010 ; 411 : 846-52
22. Leslie NR, Downes CP. PTEN function: how normal cells control it and tumour cells lose it. Biochem J. 2004; 382: 1-11
23. Damen JE, Liu L, Rosten P, et al. The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-Triphosphate 5-phosphatase. Proc Natl Acad Sci U S A. 1996; 93: 1689-93
24. Tu Z, Ninos JM, Ma Z, et al. Embryonic and hematopoietic stem cells express a novel SH2-containing inositol 5 -phosphatase isoform that partners with the Grb2 adapter protein. Blood. 2001 ; 98 : 2028-38
25. Liu Q, Sasaki T, Kozieradzki I, et al. SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival. Genes Dev. 1999; 13: 786-91
26. Locke NR, Patterson SJ, Hamilton MJ, et al. SHIP regulates the reciprocal development of T regulatory and Th 17 cells. J Immunol. 2009 ; 183 : 975-83
27. Norris FA, Majerus PW. Hydrolysis of phosphatidylinositol 3,4-bisphosphate by inositol polyphosphate 4-phosphatase isolated by affi nity elution chromatography. J Biol Chem. 1994; 269: 8716-20
28. Murray D, Honig B. Electrostatic control of the membrane targeting of C2 domains. Mol Cell. 2002; 9: 145-54
29. S hearn C T, N orris F A. B iochemical characterization of the type I inositol polyphosphate 4-phosphatase C2 domain. Biochem Biophys Res Commun. 2007; 356: 255-9
30. Ma J, Sawai H, Matsuo Y, et al. IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells. J Surg Res. 2010 ; 160 : 90-101
31. Gewinner C, Wang ZC, Richardson A, et al. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell. 2009 ; 16 : 115-25
32. Falasca M, Maff ucci T. Regulation and cellular functions of class II phosphoinositide 3-kinases. Biochem J. 2012; 443: 587-601
33. Falasca M, Hughes WE, Dominguez V, et al. The role of phosphoinositide 3-kinase C2alpha in insulin signaling. J Biol Chem. 2007; 282 : 28226-36
34. P osor Y , E ichhorn-Gruenig M , P uchkov D , e t a l. S patiotemporal control of endocytosis by phosphatidylinositol-3,4-bisphosphate. Nature. 2013 ; 499 : 233-7
35. Yoshioka K, Yoshida K, Cui H, et al. Endothelial PI3K-C2alpha, a class II PI3K, has an essential role in angiogenesis and vascular barrier function. Nat Med. 2012; 18: 1560-9
36. Maff ucci T, Cooke FT, Foster FM, et al. Class II phosphoinositide 3-kinase defi nes a novel signaling pathway in cell migration. J Cell Biol. 2005 ; 169 : 789-99
37. Visnjic D, Crljen V, Curic J, et al. The activation of nuclear phosphoinositide 3-kinase C2beta in all-Trans-retinoic acid-diff erentiated HL-60 cells. FEBS Lett. 2002; 529: 268-74
38. Harada K, Truong AB, Cai T, Khavari PA. The class II phosphoinositide 3-kinase C2beta is not essential for epidermal diff erentiation. Mol Cell Biol. 2005 ; 25 : 11122-30
39. Das M, Scappini E, Martin NP, et al. Regulation of neuron survival through an intersectin-phosphoinositide 3 -kinase C2beta-AKT pathway . Mol Cell Biol. 2007 ; 27 : 7906-17
40. Wong KA, Russo A, Wang X, et al. A new dimension to Ras function: a novel role for nucleotide-free Ras in Class II phosphatidylinositol 3-kinase beta (PI3KC2beta) regulation. PLoS One. 2012; 7: e45360
41. Backer JM. The regulation and function of Class III PI3Ks: novel roles for Vps34. Biochem J. 2008; 410: 1-17
42. Brown WJ, DeWald DB, Emr SD, et al. Role for phosphatidylinositol 3-kinase in the sorting and transport of newly synthesized lysosomal enzymes in mammalian cells. J Cell Biol. 1995; 130: 781-96
43. Schu PV, Takegawa K, Fry MJ, et al. Phosphatidylinositol 3-kinase encoded by yeast VPS34 gene essential for protein sorting. Science. 1993 ; 260 : 88-91
44. Nobukuni T, Joaquin M, Roccio M, et al. Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc Natl Acad Sci U S A. 2005; 102: 14238-43
45. Byfi eld MP, Murray JT, Backer JM. hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase. J Biol Chem. 2005 ; 280 : 33076-82
46. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008; 27: 5497-510
47. Bunney TD, Katan M. Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer. 2010; 10: 342-52
48. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007; 318: 1108-13
49. Shekar SC, Wu H, Fu Z, et al. Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit. J Biol Chem. 2005; 280: 27850-5
50. J aiswal B S, J anakiraman V , K ljavin N M, e t a l. S omatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell. 2009; 16: 463-74
51. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321: 1807-12
52. Cheung LW, Hennessy BT, Li J, et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov. 2011 ; 1 : 170-85
53. Urick ME, Rudd ML, Godwin AK, et al. PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res. 2011; 71: 4061-7
54. Sun M, Hillmann P, Hofmann BT, et al. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. Proc Natl Acad Sci U S A. 2010 ; 107 : 15547-52
55. Wu H, Shekar SC, Flinn RJ, et al. Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110alpha and are disrupted in oncogenic p85 mutants. Proc Natl Acad Sci U S A. 2009 ; 106 : 20258-63
56. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004; 304: 554
57. Levine DA, Bogomolniy F, Yee CJ, et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res. 2005 ; 11 : 2875-8
58. L ee J W, S oung Y H, K im S Y, e t a l. P IK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene. 2005 ; 24 : 1477-80
59. Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by diff erent mechanisms. Proc Natl Acad Sci U S A. 2008; 105: 2652-7
60. Benvenuti S, Frattini M, Arena S, et al. PIK3CA cancer mutations display gender and tissue specifi city patterns. Hum Mutat. 2008; 29: 284-8
61. Barbi S, Cataldo I, De Manzoni G, et al. The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type. J Exp Clin Cancer Res. 2010 ; 29 : 32
62. Liao X, Morikawa T , Lochhead P, et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res. 2012; 18: 2257-68
63. Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet. 1999 ; 21 : 99-102
64. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006 ; 7 : 606-19
65. Ciraolo E, Iezzi M, Marone R, et al. Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development. Sci Signal. 2008; 1:ra3
66. Jia S, Liu Z, Zhang S, et al. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature. 2008; 454: 776-9
67. Benistant C, Chapuis H, Roche S. A specifi c function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in De novo DNA synthesis of human colon carcinoma cells. Oncogene. 2000 ; 19 : 5083-90
68. Dbouk HA, Khalil BD, Wu H, et al. Characterization of a tumor-Associated activating mutation of the p110beta PI 3-kinase. PLoS One. 2013 ; 8 : e63833
69. Kang S, Denley A, Vanhaesebroeck B, Vogt PK. Oncogenic transformation induced by the p110beta, -γ, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci U S A. 2006 ; 103 : 1289-94
70. H ickey F B, C otter T G. B CR-ABL regulates phosphatidylinositol 3-kinase-p110γ transcription and activation and is required for proliferation and drug resistance. J Biol Chem. 2006; 281: 2441-50
71. Xie Y, Abel PW, Kirui JK, et al. Identifi cation of upregulated phosphoinositide 3-kinase γ as a target to suppress breast cancer cell migration and invasion. Biochem Pharmacol. 2013; 85: 1454-62
72. Edling CE, Selvaggi F, Buus R, et al. Key role of phosphoinositide 3-kinase class IB in pancreatic cancer. Clin Cancer Res. 2010 ; 16 : 4928-37
73. Sujobert P, Bardet V, Cornillet-Lefebvre P, et al. Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood. 2005; 106: 1063-6
74. Zhang J, Grubor V, Love CL, et al. Genetic heterogeneity of diff use large B-cell lymphoma. Proc Natl Acad Sci U S A. 2013; 110: 1398-403
75. Angulo I, Vadas O, Garcon F, et al. Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage . Science. 2013; 342: 866-71
76. Kan Z , Jaiswal BS , Stinson J , et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010 ; 466 : 869-73
77. Knowles MA, Platt FM, Ross RL, Hurst CD. Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev. 2009; 28: 305-16
78. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2: 489-501
79. Lino MM, Merlo A. PI3Kinase signaling in glioblastoma. J Neurooncol. 2011 ; 103 : 417-27
80. Carracedo A, Alimonti A, Pandolfi P P. P TEN level in tumor suppression: how much is too little? Cancer Res. 2011; 71: 629-33
81. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007; 129: 1261-74
82. Agarwal E, Brattain MG, Chowdhury S. Cell survival and metastasis regulation by Akt signaling in colorectal cancer. Cell Signal. 2013 ; 25 : 1711-19
83. Liu LZ, Zhou XD, Qian G, et al. AKT1 amplifi cation regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res. 2007 ; 67 : 6325-32
84. Carpten JD, Faber AL, Horn C, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature. 2007 ; 448 : 439-44
85. Bleeker FE, Felicioni L, Buttitta F, et al. AKT1(E17K) in human solid tumours. Oncogene. 2008; 27: 5648-50
86. Shi H, Hong A, Kong X, et al. A novel AKT1 mutant amplifi es an adaptive melanoma response to BRAF inhibition. Cancer Discov. 2014 ; 4 : 69-79
87. Bellacosa A, de Feo D, Godwin AK, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer. 1995 ; 64 : 280-5
88. Parsons DW, Wang TL, Samuels Y, et al. Colorectal cancer: mutations in a signalling pathway. Nature. 2005 ; 436 : 792
89. C heng J Q, R uggeri B , K lein W M, e t a l. A mplifi cation of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A. 1996 ; 93 : 3636-41
90. Stahl JM, Sharma A, Cheung M, et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 2004 ; 64 : 7002-10
91. Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011; 39: D945-50
92. Fedele CG, Ooms LM, Ho M, et al. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc Natl Acad Sci U S A. 2010; 107: 22231-6
93. Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer. 2011; 11: 289-301
94. Miled N, Yan Y, Hon WC, et al. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science. 2007 ; 317 : 239-42
95. Zustovich F, Lombardi G, Nicoletto O, Pastorelli D. Second-line therapy for refractory renal-cell carcinoma. Crit Rev Oncol Hematol. 2012 ; 83 : 112-22
96. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007 ; 356 : 2271-81
97. Hudes GR, Berkenblit A, Feingold J, et al. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma. Semin Oncol. 2009; 36(Suppl 3): S26-36
98. Lebwohl D, Anak O, Sahmoud T, et al. Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases. Ann N Y Acad Sci. 2013; 1291: 14-32
99. Th omas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med. 2006; 12: 122-7
100. Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol. 2010; 7: 277-85
101. L ui V W, H edberg M L, L i H , e t a l. F requent mutation of the PI3K pathway in head and neck cancer defi nes predictive biomarkers. Cancer Discov. 2013; 3: 761-9
102. Di Nicolantonio F, Arena S, Tabernero J, et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest. 2010 ; 120 : 2858-66
103. Ogino S, Liao X, Imamura Y, et al. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst. 2013; 105: 1789-98
104. Karapetis CS, Jonker D, Daneshmand M, et al. PIK3CA, BRAF, and PTEN status and benefi t from cetuximab in the treatment of advanced colorectal cancer-results from NCIC CTG/AGITG CO.17. Clin Cancer Res. 2014; 20: 744-53
105. Wu S, Gan Y, Wang X, et al. PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-Analysis. J Cancer Res Clin Oncol. 2013; 139: 891-900
106. Mao C, Yang ZY, Hu XF, et al. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-Type metastatic colorectal cancer: a systematic review and meta-Analysis. Ann Oncol. 2012; 23: 1518-25
107. Moroney JW, Schlumbrecht MP, Helgason T, et al. A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin Cancer Res. 2011 ; 17 : 6840-6
108. Janku F, Wheler JJ, Westin SN, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012; 30: 777-82
109. J anku F , W heler J J, N aing A , e t a l. P IK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res. 2013; 73: 276-84
110. Der CJ, Van Dyke T. Stopping ras in its tracks. Cell. 2 007; 129 : 855-7
111. Castellano E, Sheridan C, Th in MZ, et al. Requirement for interaction of PI3-kinase p110alpha with RAS in lung tumor maintenance. Cancer Cell. 2013 ; 24 : 617-30
112. Pacold ME, Suire S, Perisic O, et al. Crystal structure and functional analysis of Ras binding to its eff ector phosphoinositide 3-kinase γ. Cell. 2000; 103: 931-43
113. Fritsch R, de Krijger I, Fritsch K, et al. RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms. Cell. 2013 ; 153 : 1050-63
114. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006 ; 66 : 1500-8
115. Wan X, Harkavy B , Shen N, et al. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene. 2007; 26: 1932-40
116. Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008; 118: 3065-74
117. Carretero J, Shimamura T, Rikova K, et al. Integrative genomic and proteomic analyses identify targets for Lkb1-defi cient metastatic lung tumors. Cancer Cell. 2010; 17: 547-59
118. Tanwar PS, Mohapatra G, Chiang S, Engler DA, Zhang L, Kaneko-Tarui T , et al. Loss of LKB1 and PTEN tumor suppressor genes in the ovarian surface epithelium induces papillary serous ovarian cancer. Carcinogenesis. 2014; 35: 546-53
119. D upuy F , G riss T , B lagih J , e t a l. L KB1 is a central regulator of tumor initiation and pro-growth metabolism in ErbB2-mediated breast cancer . Cancer Metab. 2013; 1: 18
120. Brachmann SM, Hofmann I, Schnell C, et al. Specifi c apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplifi ed and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci U S A. 2009 ; 106 : 22299-304
121. O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3 kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010 ; 16 : 3670-83
122. W eigelt B , W arne P H, D ownward J. P IK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene. 2011; 30: 3222-33
123. G arrido-Laguna I , H ong D S, J anku F, et al. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome aft er treatment wiThearly-phase trials with targeted pathway inhibitors. PLoS One. 2012 ; 7 : e38033
124. Dienstmann R, Serpico D, Rodon J, et al. Molecular profi ling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. Mol Cancer Ther. 2012; 11: 2062-71
125. Serra V, Eichhorn PJ, Garcia-Garcia C, et al. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest. 2013 ; 123 : 2551-63
126. Hoefl ich KP, Merchant M, Orr C, et al. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res. 2012; 72: 210-19
127. Kummar S, Chen HX, Wright J, et al. Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat Rev Drug Discov. 2010; 9: 843-56
128. Juric D, Baselga J. Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors. J Clin Oncol. 2012; 30: 765-6
129. Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients wiThestrogen receptor-positive breast cancer. J Clin Oncol. 2009; 27: 2630-7
130. Garnett MJ, Edelman EJ, Heidorn SJ, et al. Systematic identifi cation of genomic markers of drug sensitivity in cancer cells. Nature. 2012 ; 483 : 570-5
131. Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-Targeted monoclonal antibodies. Cancer Res. 2009; 69: 1851-7
132. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identifi ed in human cancer are oncogenic. Proc Natl Acad Sci U S A. 2005 ; 102 : 802-7
133. Ndubaku CO, Heff ron TP, Staben ST, et al. Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-Triazol-5-yl)-5,6-dihydrobenzo[f ] imidazo[1, 2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a beta-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity. J Med Chem. 2013 ; 56 : 4597-610
134. IPI-145 shows promise in CLL patients. C ancer Discov. 2 014; 4 : 1 36
135. Chang JE, Kahl BS. PI3-kinase inhibitors in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2014; 9: 33-43
136. Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ , et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014; 370: 1008-18
137. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014; 370: 997-1007
138. Brachmann SM, Kleylein-Sohn J, Gaulis S, et al. Characterization of the mechanism of action of the pan class I PI3K inhibitor NVPBKM120 across a broad range of concentrations. Mol Cancer Ther. 2012 ; 11 : 1747-57
139. Shapiro GI, Rodon J, Bedell C, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2014; 20: 233-45
140. Y uan J , M ehta P P, Y in M J, e t a l. P F-0 4691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol Cancer Ther. 2011; 10: 2189-99
141. Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol. 2005 ; 23 : 5314-22
142. Tabernero J, Rojo F, Calvo E, et al. Dose- And schedule-dependent inhibition of the mammalian target of rapamycin pathway wiTheverolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol. 2008; 26: 1603-10
143. Motzer RJ, Escudier B, Oudard S, et al. Effi cacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebocontrolled phase III trial. Lancet. 2008 ; 372 : 449-56
144. Morrow PK , Wulf GM , Ensor J, et al. Phase I/II study of trastuzumab in combination wiTheverolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol. 2011 ; 29 : 3126-32
145. Maira SM, Stauff er F, Brueggen J, et al. Identifi cation and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther. 2008 ; 7 : 1851-63
146. Davies BR, Greenwood H, Dudley P, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012; 11: 873-87
147. Hudis C, Swanton C, Janjigian YY, et al. A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. Breast Cancer Res. 2013 ; 15 : R110